Key Takeaways
- • AI Diagnostics, a Cape Town-based medtech startup, secured $5 million in pre-Series A funding to scale its AI-powered stethoscope technology for tuberculosis detection across Africa and Asia.
- • The funding round was led by The Steele Foundation for Hope, with participation from iFSP Group and the Global Innovation Fund, plus follow-on investment from early backers Africa Health Ventures and Savant.
- • The company's core product, the Ostium digital stethoscope paired with proprietary AI.TB software, addresses a critical diagnostic gap: a national TB prevalence survey found 58% of TB-positive individuals showed no symptoms, meaning symptom-based screening misses the majority of infections.
- • South Africa faces one of the world's highest TB burdens, with 249,000 people falling ill with TB in 2024 and an estimated 54,000 deaths from the disease annually, according to the WHO 2025 World TB Report.
- • The AI model flags individuals whose lung sounds show TB-associated signals in real time, enabling frontline healthcare providers to identify cases that traditional screening methods would miss.
Summary
AI Diagnostics, a medtech startup based in Cape Town, has raised $5 million in pre-Series A funding to expand its artificial intelligence-driven tuberculosis diagnostic platform across Africa and Asia. The funding round was anchored by The Steele Foundation for Hope, with co-investors iFSP Group and the Global Innovation Fund joining the round. The startup also received follow-on backing from early-stage investors Africa Health Ventures and Savant, indicating sustained confidence in the company's clinical and commercial trajectory.
The centerpiece of AI Diagnostics' approach is the Ostium digital stethoscope, integrated with proprietary AI.TB software that analyzes lung sounds to detect tuberculosis in real time. This technology directly addresses a critical public health challenge: a national TB prevalence survey revealed that 58% of individuals testing positive for TB exhibited no symptoms, exposing the profound limitations of symptom-based screening protocols in detecting active TB cases. By flagging lung sound patterns associated with TB, the system enables frontline healthcare providers to identify infections that conventional diagnostic pathways would overlook.
The clinical and epidemiological context underscores the urgency of diagnostic innovation in the region. South Africa carries one of the highest TB disease burdens globally. According to the WHO 2025 World TB Report, 249,000 people contracted TB in South Africa in 2024, with approximately 54,000 deaths attributed to the disease. This mortality burden occurs despite TB being a curable condition, indicating that diagnostic gaps and delayed treatment initiation remain significant barriers to outcomes. The $5 million capital infusion will enable AI Diagnostics to scale production and distribution of its diagnostic platform while expanding clinical validation efforts across geographies where TB incidence remains elevated and access to conventional diagnostic infrastructure is constrained.
The centerpiece of AI Diagnostics' approach is the Ostium digital stethoscope, integrated with proprietary AI.TB software that analyzes lung sounds to detect tuberculosis in real time. This technology directly addresses a critical public health challenge: a national TB prevalence survey revealed that 58% of individuals testing positive for TB exhibited no symptoms, exposing the profound limitations of symptom-based screening protocols in detecting active TB cases. By flagging lung sound patterns associated with TB, the system enables frontline healthcare providers to identify infections that conventional diagnostic pathways would overlook.
The clinical and epidemiological context underscores the urgency of diagnostic innovation in the region. South Africa carries one of the highest TB disease burdens globally. According to the WHO 2025 World TB Report, 249,000 people contracted TB in South Africa in 2024, with approximately 54,000 deaths attributed to the disease. This mortality burden occurs despite TB being a curable condition, indicating that diagnostic gaps and delayed treatment initiation remain significant barriers to outcomes. The $5 million capital infusion will enable AI Diagnostics to scale production and distribution of its diagnostic platform while expanding clinical validation efforts across geographies where TB incidence remains elevated and access to conventional diagnostic infrastructure is constrained.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.